168 related articles for article (PubMed ID: 1723408)
1. Serum markers in germ cell neoplasms.
Bartlett NL; Freiha FS; Torti FM
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1245-60. PubMed ID: 1723408
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
3. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
4. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
Swanson DA
Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
[No Abstract] [Full Text] [Related]
5. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of pre-orchidectomy serum tumor markers in non seminomatous germ cell tumors of the testis (N.S.G.C.T.T.).
Boccon-Gibod L; Le Doze H; Steg A
Prog Clin Biol Res; 1985; 203():93-5. PubMed ID: 2421347
[TBL] [Abstract][Full Text] [Related]
7. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in testicular cancer].
Mann K
Urologe A; 1990 Mar; 29(2):77-86. PubMed ID: 2158684
[TBL] [Abstract][Full Text] [Related]
9. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
10. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
[TBL] [Abstract][Full Text] [Related]
11. [Clinical studies of testicular tumor. II. Analysis of 30 patients with nonseminomatous testicular tumor].
Tsukamoto T; Kumamoto Y; Ohmura K; Tsunekawa T; Yamazaki K
Hinyokika Kiyo; 1986 Jul; 32(7):999-1011. PubMed ID: 2430437
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers--personal experience. Multidisciplinary treatment of disseminated germ cell tumor in full use of tumor markers].
Tobisu K
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1221-6. PubMed ID: 1711304
[TBL] [Abstract][Full Text] [Related]
13. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
Morris MJ; Bosl GJ
J Urol; 2000 Mar; 163(3):796-801. PubMed ID: 10687980
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
15. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
16. Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period.
Tröbs RB; Krauss M; Geyer C; Tannapfel A; Körholz D; Hirsch W
Klin Padiatr; 2007; 219(3):146-51. PubMed ID: 17525908
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
18. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment.
Murugaesu N; Schmid P; Dancey G; Agarwal R; Holden L; McNeish I; Savage PM; Newlands ES; Rustin GJ; Seckl MJ
J Clin Oncol; 2006 Oct; 24(30):4862-6. PubMed ID: 17050871
[TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors.
Gilligan TD; Seidenfeld J; Basch EM; Einhorn LH; Fancher T; Smith DC; Stephenson AJ; Vaughn DJ; Cosby R; Hayes DF;
J Clin Oncol; 2010 Jul; 28(20):3388-404. PubMed ID: 20530278
[TBL] [Abstract][Full Text] [Related]
20. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
